Anti-Mullerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition

Sowers, Mary Fran; Eyvazzadeh, Aimee D.; McConnell, Daniel S.; Yosef, Matheos; Jannausch, Mary; Zhang, Daowen; Harlow, Sioḃán D.; Randolph, John F.

doi:10.1210/jc.2008-0567

Cited by 338 publications

(203 citation statements)

References 32 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…One study suggests that AMH levels decrease to undetectable levels 5 years before the onset of the menopausal status (date of last menses), so undetectable plasma levels of AMH suggest a pending menopausal status (Sowers et al 2008). However, longitudinal studies are required in order to establish if different or undetectable levels of AMH could predict timing of onset of postmenopausal status: this knowledge could be useful in the determination of menopausal status in chemotherapy-treated patients.…”

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mü llerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Bozza¹,

Puglisi²,

Lambertini³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…[51][52][53][54] The age-related decrease in the number of follicles in the ovary is reflected in the number of antral follicles seen on ultrasound 55 ; in declining levels of AMH, 12 which is expressed only in small growing follicles 11 ; and in decreased levels of inhibin B, which is constitutively secreted from granulosa cells in FSH-dependent growing follicles. 56 Inhibin B plays an extremely important role as a gonadal feedback modulator of FSH secretion in early ovarian aging, with declining levels of inhibin B associated with increasing levels of FSH.…”

Section: Maintenance Of Follicle Development and Estrogen Secretion Imentioning

confidence: 99%

Endocrinology of the Menopause

Hall

2015

Endocrinology and Metabolism Clinics of North America

127

View full text Add to dashboard Cite

In women, age-related changes in ovarian function begin in the mid-30s with decreased fertility and compensatory hormonal changes in the hypothalamus-pituitary-gonadal axis that maintain follicle development and estrogen secretion in the face of a waning pool of ovarian follicles. The menopause transition is characterized by marked variability in follicle development, ovulation, bleeding patterns, and symptoms of hyper- and hypoestrogenism. The menopause, which is clinically defined by the last menstrual period, is followed by the consistent absence of ovarian secretion of estradiol.

show abstract

“…A hypot he sis stan ds that this pro ce ss is ini tia ted when the to tal of number of oo cytes reac hes ap proxi ma te ly 25,000 and that wo man, un der physio lo gi cal con di tion, reaches this thres ho ld at about 37-38 yea rs of age (42). At me no pau se, the num ber of oo cytes has dec reased to so me hun dre ds (43).…”

Section: Amh As In DI Ca Tor Of Ova Rian Agi Ng Throug Hout Rep Ro Dumentioning

confidence: 99%

Anti-Müllerian hormone: A unique biochemical marker of gonadal development and fertility in humans

Zec¹,

Tišlarić-Medenjak²,

Megla³

et al. 2011

Biochem Med

View full text Add to dashboard Cite

An ti-Mülle rian hor mo ne (AMH) is a glycop ro tein be lon gi ng to the tran sfor mi ng growth fac to rs (TGF-β). AMH plays a fun da men tal ro le in the regres sion of Mülle rian duc ts in ma le em bryo. In its ab sen ce, Mülle rian duc ts de ve lop in to fe ma le in ner rep ro duc ti ve or ga ns. In boys, it is sig ni fi can tly pro du ced in Ser to li cel ls of tes tes un til pu ber ty and then slowly dec rea ses to re si dual va lues for the re st of the me n's li fe. AMH ser ves as a bioc he mical mar ker of the pre sen ce of tes tes in cryptor chi dic ma les. In fe ma les, AMH is sec re ted by gra nu lo sa cel ls of sma ll fol lic les in the ova ry. Se rum va lues are al mo st un de tec tab le du ri ng in fan cy and then ra pid ly in crea se wi th the on set of pu ber ty, refl ec ti ng the ini tial rec ruit me nt of pri mor dial fol lic les. AMH is pro du ced in growi ng fol lic les un til they rea ch a sta ge when do mi na nt fol lic le is de tac hed from a co ho rt of an tral fol lic les. The mea su re me nt of se rum AMH le ve ls du ri ng wo ma n's rep ro duc ti ve li fe rep re sen ts an ideal tool for the as ses sme nt of the ova rian fol li cu lar re ser ve. The ad van ta ge of AMH in re la tion to the ova rian ste roid hor mo nes is that se rum le ve ls do not fl uc tua te sig ni fi can tly du ri ng the men strual cycle. In ad di tion, cir cu la ting AMH stron gly cor re la tes wi th an tral fol lic le cou nt (AFC), vi sua li zed by ul tra sou nd in the fol li cu lar pha se of the cycle. As the num ber and qua li ty of the oo cytes di mi ni sh throug hout the wo ma n's rep ro duc ti ve li fe, se rum con cen tra tio ns of AMH gra dual ly dec rea se and fa ll be low de tec tab le le ve ls in me no pau se. This cou ld be of par ti cu lar in te re st in sub fer ti le and in fer ti le wo men un der goi ng as sis ted rep ro duc ti ve tec hniques (ART) in ac hie vi ng preg nan cy. Key wor ds: an ti-Mülle rian hor mo ne; ova rian re ser ve; sper ma to ge ne sis; in fer ti li ty; sex-diff e ren tia tion Review In tro duc tionAn ti-Mülle rian hor mo ne (AMH) is a 140-kDa di meric glycop ro tein hor mo ne and be lon gs to the transfor mi ng growth fac to r-β (TGF-β) fa mi ly. AMH is synthe si zed as a lar ge pre cur sor wi th a sho rt sig nal sequen ce fol lowed by the pre-pro hor mo ne that for ms ho mo di me rs. Prior to sec re tion, the ma tu re hor mo ne un der goes glyco syla tion and di me ri zation to pro du ce a 144-kDa di mer com po sed of iden ti cal di sul phi de-lin ked 72-kDa mo no mer subu ni ts. Ea ch mo no mer con tai ns an N-ter mi nal domain (al so cal led the "pro re gio n") and a C-ter minal do main (al so cal led the "ma tu re re gio n"); it is be lie ved that N-ter mi nal do main ac cen tua tes the ac ti vi ty of the C-ter mi nal do main in whi ch re si des the bioac ti vi ty of the mo le cu le (1). Du ri ng cytoplas mic tran sit, be tween 5 and 20% of AMH is cleaved at a spe ci fi c si te be tween the N-ter mi nal and the C-ter mi nal do main of the 72-kDa mo no mer, to fo rm tw...

show abstract

Anti-Mullerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition

Cited by 338 publications

References 32 publications

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients

Endocrinology of the Menopause

Anti-Müllerian hormone: A unique biochemical marker of gonadal development and fertility in humans

Contact Info

Product

Resources

About